Skip to main content
CLDX
NASDAQ Life Sciences

Celldex Therapeutics 获得 3.45 亿美元公开发行资金，承销商行使全部认购权

feedReported by GlobeNewswire
Sentiment info
Neutral
Importance info
7
Price
$31.33
Mkt Cap
$2.086B
52W Low
$14.4
52W High
$34.52
Market data snapshot near publication time

summarizeSummary

Celldex Therapeutics 已宣布完成公开发行，获得约 3.45 亿美元的总收益。该最终金额包括承销商行使购买额外 1,551,750 股普通股的选项，价格为每股 29.00 美元。这次融资是在公司于 4 月 1 日宣布发行并于 4 月 2 日确定发行价格之后进行的，此前发行价格指出总收益为 3 亿美元。该发行是在公司于 3 月 27 日展示其研究性药物 barzolvolimab 的非常积极的 2 期数据之后战略性地启动的。确认的资本注入为 Celldex 的临床管线提供了大量资金，特别是推进 barzolvolimab 的发展，但也最终确定了对现有股东的稀释影响。投资者现在将监测这些资金的使用和即将到来的临床里程碑。

在该公告发布时，CLDX的交易价格为$31.33，交易所为NASDAQ，所属行业为Life Sciences，市值约为$20.9亿。 52周交易区间为$14.40至$34.52。 这则新闻被评估为中性市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CLDX - Latest Insights

CLDX
Apr 29, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Celldex Seeks Shareholder Approval for 3.4M Share Increase in Equity Incentive Plan
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 06, 2026, 10:53 AM EDT
Source: GlobeNewswire
Importance Score:
7
Celldex Therapeutics Secures $345M from Public Offering, Underwriters Fully Exercise Option
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 5:14 PM EDT
Filing Type: 424B5
Importance Score:
8
Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 02, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Celldex Therapeutics Prices $300 Million Public Offering, Significant Dilution Expected
Sentiment: Negative
View Wiseek Article
CLDX
Apr 01, 2026, 9:48 PM EDT
Source: Reuters
Importance Score:
8
$300 Million Stock Offering Priced by Celldex at $29.00 Per Share
Sentiment: Neutral
View Wiseek Article
CLDX
Apr 01, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex Proposes Public Stock Offering to Fund Barzolvolimab Commercialization
Sentiment: Negative
View Wiseek Article
CLDX
Mar 27, 2026, 10:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Celldex's Barzolvolimab Shows Profound, Durable Quality of Life Improvements in Phase 2 Urticaria Studies
Sentiment: Positive
View Wiseek Article
CLDX
Mar 01, 2026, 9:45 AM EST
Source: GlobeNewswire
Importance Score:
8
Barzolvolimab Retreatment Shows Profound Efficacy in Cold Urticaria and SD, Reinforcing Best-in-Class Profile
Sentiment: Positive
View Wiseek Article
CLDX
Feb 27, 2026, 2:45 PM EST
Source: GlobeNewswire
Importance Score:
9
Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
Sentiment: Positive
View Wiseek Article
CLDX
Feb 25, 2026, 4:06 PM EST
Filing Type: 10-K
Importance Score:
8
Celldex Therapeutics Advances Multiple Clinical Programs, Secures Liquidity Through 2027
Sentiment: Positive
View Wiseek Article